Equities analysts predict that Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) will report $17.36 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Kymera Therapeutics’ earnings, with estimates ranging from $15.43 million to $20.00 million. Kymera Therapeutics reported sales of $18.70 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 7.2%. The firm is expected to announce its next quarterly earnings results before the market opens on Monday, January 1st.
According to Zacks, analysts expect that Kymera Therapeutics will report full-year sales of $97.51 million for the current fiscal year, with estimates ranging from $64.22 million to $137.50 million. For the next year, analysts anticipate that the company will post sales of $93.07 million, with estimates ranging from $19.24 million to $189.30 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Kymera Therapeutics.
Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.09). Kymera Therapeutics had a negative net margin of 137.60% and a negative return on equity of 27.16%. The company had revenue of $15.30 million during the quarter, compared to analyst estimates of $21.31 million. During the same period in the previous year, the company posted ($0.29) EPS. The company’s quarterly revenue was up 19.5% on a year-over-year basis.
Shares of NASDAQ:KYMR opened at $33.88 on Friday. The business’s 50 day simple moving average is $38.97 and its two-hundred day simple moving average is $48.74. The firm has a market cap of $1.75 billion, a P/E ratio of -16.45 and a beta of 2.01. Kymera Therapeutics has a 52-week low of $33.62 and a 52-week high of $69.12.
In other news, Director Bvf Partners L. P/Il bought 95,901 shares of the firm’s stock in a transaction on Thursday, January 27th. The stock was acquired at an average cost of $38.33 per share, with a total value of $3,675,885.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bvf Partners L. P/Il purchased 34,408 shares of Kymera Therapeutics stock in a transaction dated Monday, January 31st. The stock was bought at an average price of $40.70 per share, with a total value of $1,400,405.60. The disclosure for this purchase can be found here. Insiders acquired 403,076 shares of company stock valued at $15,375,973 over the last three months. Company insiders own 23.28% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Kymera Therapeutics by 14.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,760 shares of the company’s stock valued at $159,000 after purchasing an additional 488 shares in the last quarter. Norges Bank purchased a new position in shares of Kymera Therapeutics in the fourth quarter valued at $3,439,000. BlackRock Inc. grew its position in shares of Kymera Therapeutics by 11.7% in the fourth quarter. BlackRock Inc. now owns 3,397,540 shares of the company’s stock valued at $215,709,000 after purchasing an additional 357,109 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Kymera Therapeutics by 48.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 267,790 shares of the company’s stock valued at $17,002,000 after purchasing an additional 87,583 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Kymera Therapeutics by 2.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 17,739 shares of the company’s stock valued at $1,120,000 after purchasing an additional 423 shares in the last quarter. Institutional investors own 75.06% of the company’s stock.
Kymera Therapeutics Company Profile (Get Rating)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Get a free copy of the StockNews.com research report on Kymera Therapeutics (KYMR)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.